VIMEDIMEX BINH DUONG ONE MEMBER COMPANY LIMITED

VIMEDIMEX BINH DUONG ONE MEMBER COMPANY LIMITED (MST: 3701538659) is a pharmaceutical trading company headquartered at Lot 18 L1-2, VSIP II Industrial Park, Hoa Phu Ward, Thu Dau Mot City, Binh Duong Province. Officially registered in 2009, the company operates as a one-member limited liability company, wholly owned by Vimedimex Medi-Pharma Joint Stock Company. It is active, with large-scale operations and a workforce that once reached over 1,800 staff.

At the top is Chairwoman Trinh Ngoc Duyen, with key roles also held by Director Hoang Thi Mai Anh and Deputy Director Le Thanh Long. The company's main business is in wholesale distribution of pharmaceuticals, medical devices, biologicals, and related health products. It also handles food distribution, beauty products, and operates retail points specializing in pharmaceutical goods.

The financial story of VIMEDIMEX BINH DUONG is more sobering. Sales plunged by more than 51% in 2023, falling to USD 137.81 million, from over USD 480 million just two years earlier. Total assets also dropped sharply, from USD 175.7 million in 2021 to just USD 39.68 million in 2023, a nearly 77% contraction over two years. Even with this decline, the company posted USD 512,817 in profit, though that’s a 59.41% drop from the previous year.

Owner's equity stands at USD 2.19 million, and net worth is slightly lower at USD 2.17 million. The firm does have positive working capital of around USD 1.99 million, which keeps its operations from falling into liquidity distress in the short term, but the overall trajectory—shrinking revenues, declining assets, lower profit—raises structural questions.

There’s no question that VIMEDIMEX BINH DUONG ONE MEMBER COMPANY LIMITED is still functioning and still profitable, but it’s not where it used to be. The name carries weight, the ownership is solid, and the regulatory compliance seems intact. However, the massive drop in scale cannot be ignored. It’s no longer a high-growth enterprise—it’s a company in contraction. Whether this reflects market shifts, internal restructuring, or strategic withdrawal remains to be seen. But what’s certain is that its current status tells a different story from its past.